ovarian cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Age between 18 and 80 years (inclusive); (2) Patients with ovarian cancer who, after clinical evaluation, can undergo complete tumor resection (R0) via primary cytoreductive surgery, or who can achieve complete resection (R0) via interval cytoreductive surgery following neoadjuvant therapy; (3) Ovarian cancer as a sole diagnosis, without concomitant occurrence of other malignancies; (4) Availability of the patient’s clinical information and definitive pathological diagnosis; (5) Ability to comply with long-term follow-up (20 months postoperatively), including regular re-examinations and blood sample collection; (6) Patient’s consent to participate in the follow-up program and to provide follow-up information; (7) Informed consent obtained from the patient or the patient’s legal representative, and the patient is able to cooperate in completing the requirements of the study.
Exclusion criteria
Exclusion criteria: (1) Patients with severe comorbidities resulting in a life expectancy shorter than the study follow-up period; (2) Patients who have received a blood transfusion within three months prior to enrollment; (3) Patients who are HIV-positive or have other immunodeficiency disorders; (4) Pregnant patients; (5) Patients with alcohol or drug abuse; (6) Any other conditions deemed by the investigators as potentially affecting study outcomes or violating ethical principles.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral blood ctDNA level;Progression free survival; | — |
Countries
China
Contacts
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ShenZhen